Top 10 Biotech Stocks To Watch For 2019


When a small biotech reports bad news, its stock can plunge. On the other hand, when a small biotech announces good news, its share price can skyrocket. 

Three small biotechs have enjoyed some very good news this year. Shares of Amarin Corp. (NASDAQ:AMRN), Fate Therapeutics (NASDAQ:FATE), and Intercept Pharmaceuticals (NASDAQ:ICPT) are at 52-week highs, with Fate at an all-time high. What caused these small biotech stocks to soar — and are they still smart picks to buy?

Image source: Getty Images.

1. Amarin: Something fishy is going on (in a positive way)

Amarin’s share price has nearly quadrupled this year. Even better, the stock has skyrocketed over 450% in just the last couple of weeks. This great performance stems from the biotech announcing results on Sept. 24 of a cardiovascular outcomes study of Vascepa, Amarin’s omega3 fatty acid drug derived from fish.

Top 10 Biotech Stocks To Watch For 2019: ArQule Inc.(ARQL)


Advisors’ Opinion:

  • [By Joseph Griffin]

    ArQule (NASDAQ:ARQL)‘s stock had its “buy” rating restated by equities researchers at Needham & Company LLC in a research report issued to clients and investors on Tuesday, Marketbeat Ratings reports. They currently have a $6.00 price target on the biotechnology company’s stock, up from their prior price target of $5.00. Needham & Company LLC’s price target suggests a potential upside of 134.38% from the company’s previous close.

  • [By Lisa Levin] Gainers
    Foot Locker, Inc. (NYSE: FL) rose 15.3 percent to $53.50 in pre-market trading after the company reported better-than-expected results for its first quarter.
    Evofem Biosciences, Inc. (NASDAQ: EVFM) rose 10.4 percent to $4.58 in pre-market trading. Evofem Biosciences reported closing of public offering of common stock and warrants.
    Resonant Inc. (NASDAQ: RESN) rose 7.3 percent to $4.88 in pre-market trading after declining 1.94 percent on Thursday.
    SolarEdge Technologies, Inc. (NASDAQ: SEDG) shares rose 5.7 percent to $59.65 in pre-market trading after falling 8.43 percent on Thursday.
    Yirendai Ltd. (NYSE: YRD) rose 5 percent to $30.00 in pre-market trading after reporting Q1 results.
    Deckers Outdoor Corp (NYSE: DECK) rose 4.9 percent to $108.75 in pre-market trading after reporteingd better-than-expected results for its fiscal fourth quarter.
    Blue Apron Holdings, Inc. (NYSE: APRN) rose 4.2 percent to $3.21 in pre-market trading after gaining 3.70 percent on Thursday.
    Recro Pharma, Inc. (NASDAQ: REPH) rose 4 percent to $5.85 in pre-market trading after dropping 54.67 percent on Thursday.
    ArQule, Inc. (NASDAQ: ARQL) rose 3.8 percent to $4.70 in pre-market trading after gaining 4.86 percent on Thursday.
    Babcock & Wilcox Enterprises, Inc. (NYSE: BW) shares rose 2.9 percent to $2.85 in pre-market trading after climbing 7.78 percent on Thursday.
    Bilibili Inc. (NASDAQ: BILI) shares rose 2.5 percent to $14.20 in pre-market trading after surging 11.33 percent on Thursday.


    Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

  • [By Stephan Byrd]

    ArQule, Inc. (NASDAQ:ARQL)’s share price rose 6.2% during trading on Thursday . The stock traded as high as $5.21 and last traded at $5.15. Approximately 955,706 shares changed hands during mid-day trading, a decline of 23% from the average daily volume of 1,244,948 shares. The stock had previously closed at $4.85.

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on ArQule (ARQL)


    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Stephan Byrd]

    ArQule, Inc. (NASDAQ:ARQL) Director Ronald M. Lindsay acquired 23,900 shares of the company’s stock in a transaction on Thursday, May 10th. The stock was acquired at an average price of $2.67 per share, for a total transaction of $63,813.00. Following the purchase, the director now directly owns 43,900 shares of the company’s stock, valued at $117,213. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on ArQule (ARQL)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 10 Biotech Stocks To Watch For 2019: Amgen Inc.(AMGN)

Advisors’ Opinion:

  • [By Cory Renauer]

    The market for complex therapies that train living cells to attack cancer is taking baby steps, but there’s still a lot of enthusiasm for experimental drugs coming through the pipeline from bluebird bio (NASDAQ:BLUE) and it’s big biotech partner Celgene (NASDAQ:CELG). That enthusiasm fell a notch after Amgen (NASDAQ:AMGN) released exciting data from a handful of patients that suggests it’s found a much easier way to achieve the same goal. 

  • [By Stephan Byrd]

    PNC Financial Services Group Inc. trimmed its stake in Amgen, Inc. (NASDAQ:AMGN) by 0.3% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 2,120,853 shares of the medical research company’s stock after selling 6,484 shares during the quarter. PNC Financial Services Group Inc.’s holdings in Amgen were worth $391,489,000 as of its most recent SEC filing.

  • [By Chris Lange]

    Amgen Inc. (NASDAQ: AMGN) saw its short interest rise to 10.78 million shares from the previous level of 9.98 million. Shares were last seen trading at $196.64, in a 52-week trading range of $163.31 to $201.23.

  • [By Cory Renauer]

    Ajovy prevents migraine headaches by targeting the calcitonin gene-related peptide (CGRP), and it isn’t the first of its kind to earn an approval. The Food and Drug Administration green-lighted Aimovig from partners Amgen (NASDAQ:AMGN) and Novartis (NYSE:NVS) in May, and by August, weekly prescriptions data prompted a Leerink analyst to predict $480 million in 2019 sales.

Top 10 Biotech Stocks To Watch For 2019: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors’ Opinion:

  • [By Keith Speights]

    It’s not exactly David vs. Goliath. However, Bellicum Pharmaceuticals (NASDAQ:BLCM) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are definitely in different leagues right now. Both are clinical-stage biotechs, but Bellicum’s market cap is less than $350 million while Alnylam’s market cap is close to $10 billion.

  • [By Brian Orelli]

    Earlier this week, Dicerna released promising interim phase I data for its lead drug, DCR-PHXC, in patients with primary hyperoxaluria type 1 and type 2. The company plans to start a trial to be used to support an FDA approval in the first quarter of 2019, but that’ll put it behind Alnylam Pharmaceuticals (NASDAQ:ALNY), which is about to start a phase 3 study testing its drug, lumasiran, in patients with primary hyperoxaluria type 1. Hopefully, Dicerna can use some of its new capital to help accelerate enrollment in its trial to try to catch up to Alnylam.

  • [By Jim Crumly]

    Commercial success for Tegsedi is not a done deal even if it’s approved worldwide; Alnylam Pharmaceuticals’ (NASDAQ:ALNY) competing drug patisiran was approved by the FDA on Aug. 10. Alnylam’s clinical testing showed cardiac benefits for patients whose cardiovascular systems have been affected by the disease, and Alnylam believes that will give patisiran an advantage over Tegsedi. But in the conference call, Akcea executives brushed off that concern and pointed to the advantage Tegsedi has in being an injection that can be delivered at home, versus patisiran, which is administered intravenously in a clinic. We shall see.

  • [By Brian Orelli]

    Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) were up 19% at 12:04 p.m. EDT on Monday after rival Pfizer (NYSE:PFE) released data for its transthyretin amyloid (ATTR) drug tafamidis at the ESC Congress 2018, which were also published in the New England Journal of Medicine. Earlier this month, Alnylam got its ATTR drug, Onpattro, approved by the Food and Drug Administration. Shares of Ionis Pharmaceuticals (NASDAQ:IONS) and Akcea Therapeutics (NASDAQ:AKCA), which are jointly developing another ATTR drug, Tegsedi, are up 10% and 2.6% respectively.

  • [By Motley Fool Transcription]

    Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Q4 2019 Earnings Conference CallFeb. 7, 2017, 4:30 p.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

  • [By Logan Wallace]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Although Alnylam has a broad and promising pipeline, we note that most candidates are in mid stages of development. These candidates still have a long way to go before hitting the market. The company relies highly on collaborators for funding. Any development/regulatory setback would be a negative for the company.  However, Alnylam reported positive data from the ATLAS study in the first quarter which led to regulatory filings for its late-stage pipeline candidate patisiran and the FDA set an action date of Aug 11, 2018. The company along with its partners Sanofi and The Medicines Company, restarted fitusiran's ATLAS phase III study and advanced inclisiran in the ORION-9, -10, and -11 phase III studies, respectively, with results expected for both programs in 2019. Alnylam expects to achieve the profile of three marketed products by the end of 2020.”

Top 10 Biotech Stocks To Watch For 2019: Biogen Idec Inc(BIIB)


Advisors’ Opinion:

  • [By Ethan Ryder]

    Russell Investments Group Ltd. boosted its holdings in Biogen (NASDAQ:BIIB) by 40.1% in the first quarter, according to its most recent filing with the SEC. The institutional investor owned 183,809 shares of the biotechnology company’s stock after buying an additional 52,654 shares during the period. Russell Investments Group Ltd.’s holdings in Biogen were worth $50,222,000 as of its most recent SEC filing.

  • [By Sean Williams]

    Of course, my “bet against all Alzheimer’s drugs” thesis took a bit of a hit last week when biotech blue-chip Biogen (NASDAQ:BIIB), which is working alongside partner Eisai (NASDAQOTH:ESALY), reported positive mid-stage data on blockbuster hopeful BAN2401.

  • [By Cory Renauer]

    Healthcare is something that people need no matter what’s happening in the economy, so the sector is full of great stocks for investors seeking steadily growing income streams. That said, Abiomed, Inc. (NASDAQ:ABMD), Biogen Inc. (NASDAQ:BIIB), and Canopy Growth Corporation (NYSE:CGC) are three popular healthcare stocks that would make horrible additions to a retirement portfolio.

  • [By George Budwell]

    Not surprisingly, biotech titans Celgene (NASDAQ:CELG) and Biogen (NASDAQ:BIIB) are among the leaders in this ongoing biopharma revolution. So, with that theme in mind, let’s attempt to gauge which of these top biotechs is the more attractive long-term buy for investors right now.

  • [By Cory Renauer]

    Biotech traders get heaps of attention, but buying promising young drugmakers and holding them for the long term is a far easier way to get rich. Case in point: Spreading $10,000 evenly among shares of Biogen Inc. (NASDAQ:BIIB), Celgene Corporation (NASDAQ:CELG), and Gilead Sciences Inc. (NASDAQ:GILD) around this time in 1998 would have made you a millionaire already. 

  • [By Chris Lange]

    Biogen Inc. (NASDAQ: BIIB) shares jumped early on Friday after the firm, in conjunction with Eisai out of Japan, announced positive results from a midstage Alzheimer’s study. The topline results came from the Phase 2 study with BAN2401, an anti-amyloid beta protofibril antibody, in 856 patients with early Alzheimer’s disease.

Leave a Reply

Your email address will not be published.